Life Biosciences has dosed its first patient with ER-100, a cellular rejuvenation therapy aiming to reverse age-related sight loss, in a first-ever human clinical trial approved by the FDA.
It will be the first time ER-100 technology they claim can reverse aging in cells has been tested on a human.
# Longevity Startup Doses First Human in Bid to Reverse Age-Related Sight Loss
Source: [https://www.wired.com/story/longevity-startup-doses-first-human-in-bid-to-reverse-age-related-sight-loss/](https://www.wired.com/story/longevity-startup-doses-first-human-in-bid-to-reverse-age-related-sight-loss/)
The FDA recently approved the cellular rejuvenation therapy ER\-100 for human clinical trials\.
Photo\-Illustration: WIRED Staff; Getty Images
A longevity startuphas dosed its first patient with a drug to reverse age\-related sight loss\.
Life Biosciences is testing its ER\-100 drug, which the company claims[has](https://www.lifebiosciences.com/life-biosciences-presents-at-aao-on-partial-epigenetic-reprogramming/)restored vision in monkeys, for safety and side effects in a study of around 18 adults over the next year\.
It will be targeting patients with glaucoma and NAION, two conditions that cause damage to crucial cells in the optic nerve, which transmits visual information from the back of the eye to the brain\. ER\-100 is designed to rejuvenate those cells so that they work again and restore sight\.
It is the first\-ever cellular rejuvenation therapy using this technology to receive FDA clearance to enter human clinical trials, and hence the first chance to test whether the technology can “ameliorate human disease,” according to Life Biosciences cofounder and professor of Genetics at Harvard Medical School, David Sinclair\.
Aging biology—understanding how the body’s cells and functions deteriorate over time—is at the[root of longevity science](https://www.wired.com/story/aging-might-not-be-inevitable-wired-health-venki-ramakrishnan/)\. ER\-100 is the focus of major interest across biotech for its potential to reverse cellular aging\. Life Biosciences, based in Boston, says it is developing applications for its technology to tackle a host of age\-related diseases in a variety of organs, like[fatty liver disease](https://www.lifebiosciences.com/pipeline/)\.
“Our research has suggested that aging is driven in large part by the loss of epigenetic information, not irreversible damage\. This clinical study represents the first opportunity to test whether restoring that information can ameliorate human disease,” Sinclair said\.
- How[AI Agents](https://www.wired.com/story/ai-agents-plunged-tech-world-into-chaos/)Plunged the Tech World Into Chaos
- **In your inbox:**Will Knight’s[AI Lab](https://www.wired.com/newsletter/ai-lab?sourceCode=BottomStories)explores advances in AI
LifeBioSciences has dosed the first patient in a Phase 1 trial of ER-100, an epigenetic restoration drug candidate for optic neuropathies, marking a milestone in the development of therapies for vision impairment.
First person treated in a gene therapy trial using partial reprogramming to rejuvenate cells, aiming to treat glaucoma by regenerating optic nerve neurons.
Brian Armstrong announces that NewLimit has developed a prototype drug that reverses cellular aging in human cells, with a clinical trial scheduled for next year, and has raised $435M in Series C funding led by Founders Fund.
David Sinclair plans to test an oral epigenetic reprogramming drug, SL-100, in the XPrize competition for whole-body rejuvenation, aiming for a 10-year age reversal.
DeepMind's Co-Scientist is helping biologists identify genetic factors that reverse cellular aging by mining literature and analyzing screening data, reducing analysis time from months to days.